IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next?

Shares of IceCure Medical Ltd (NASDAQ:ICCMGet Free Report) were down 0.4% on Thursday . The stock traded as low as $1.12 and last traded at $1.15. Approximately 341,936 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 574,286 shares. The stock had previously closed at $1.16.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ICCM. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $2.50 price objective on shares of IceCure Medical in a research note on Wednesday, November 27th.

View Our Latest Stock Analysis on ICCM

IceCure Medical Stock Down 0.4 %

The firm has a market cap of $52.46 million, a price-to-earnings ratio of -3.97 and a beta of 0.50. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $0.74 and a 200-day moving average price of $0.71.

Institutional Trading of IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new position in shares of IceCure Medical Ltd (NASDAQ:ICCMFree Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is owned by institutional investors.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

See Also

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.